Your browser doesn't support javascript.
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).
Pagano, Livio; Salmanton-García, Jon; Marchesi, Francesco; Busca, Alessandro; Corradini, Paolo; Hoenigl, Martin; Klimko, Nikolai; Koehler, Philipp; Pagliuca, Antonio; Passamonti, Francesco; Verga, Luisa; Vísek, Benjamin; Ilhan, Osman; Nadali, Gianpaolo; Weinbergerová, Barbora; Córdoba-Mascuñano, Raúl; Marchetti, Monia; Collins, Graham P; Farina, Francesca; Cattaneo, Chiara; Cabirta, Alba; Gomes-Silva, Maria; Itri, Federico; van Doesum, Jaap; Ledoux, Marie-Pierre; Cernan, Martin; Jaksic, Ozren; Duarte, Rafael F; Magliano, Gabriele; Omrani, Ali S; Fracchiolla, Nicola S; Kulasekararaj, Austin; Valkovic, Toni; Poulsen, Christian Bjørn; Machado, Marina; Glenthøj, Andreas; Stoma, Igor; Rácil, Zdenek; Piukovics, Klára; Navrátil, Milan; Emarah, Ziad; Sili, Uluhan; Maertens, Johan; Blennow, Ola; Bergantim, Rui; García-Vidal, Carolina; Prezioso, Lucia; Guidetti, Anna; Del Principe, Maria Ilaria; Popova, Marina.
  • Pagano L; Hematology, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy. Livio.Pagano@unicatt.it.
  • Salmanton-García J; Università Cattolica del Sacro Cuore, Rome, Italy. Livio.Pagano@unicatt.it.
  • Marchesi F; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Excellence Center for Medical Mycology (ECMM), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Busca A; Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Corradini P; Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Hoenigl M; Stem Cell Transplant Center, AOU Citta' Della Salute E Della Scienza, Turin, Italy.
  • Klimko N; University of Milan and Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
  • Koehler P; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, USA.
  • Pagliuca A; Clinical and Translational Fungal-Working Group, University of California San Diego, La Jolla, CA, USA.
  • Passamonti F; Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Verga L; North-Western State Medical University Named After Iliá Ilich Méchnikov, Saint-Petersburg, Russia.
  • Vísek B; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Excellence Center for Medical Mycology (ECMM), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Ilhan O; Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Nadali G; Department of Hematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
  • Weinbergerová B; Department of Medicine and Surgery, University of Insubria, ASST Sette Laghi, Ospedale Di Circolo of Varese, Varese, Italy.
  • Córdoba-Mascuñano R; Azienda Ospedaliera San Gerardo - Monza, Monza, Italy.
  • Marchetti M; Università Milano-Bicocca, Milan, Italy.
  • Collins GP; University Hospital Hradec Králové, Hradec Králové, Czech Republic.
  • Farina F; Ankara University, Ankara, Turkey.
  • Cattaneo C; Policlinico Borgo Roma Verona, Verona, Italy.
  • Cabirta A; Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
  • Gomes-Silva M; Fundacion Jimenez Díaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain.
  • Itri F; Hematology and BMT Unit, Azienda Ospedaliera Nazionale SS. Antonio E Biagio E Cesare Arrigo, Alessandria, Italy.
  • van Doesum J; NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK.
  • Ledoux MP; Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Cernan M; ASST-Spedali Civili, Brescia, Italy.
  • Jaksic O; Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Duarte RF; Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Magliano G; Portuguese Institute of Oncology, Lisbon, Portugal.
  • Omrani AS; San Luigi Gonzaga Hospital - Orbassano, Orbassano, Italy.
  • Fracchiolla NS; University Medical Center Groningen, Groningen, Netherlands.
  • Kulasekararaj A; ICANS, Strasbourg, France.
  • Valkovic T; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic.
  • Poulsen CB; Department of Hematology, University Hospital Dubrava, Zagreb, Croatia.
  • Machado M; Hospital Universitario Puerta de Hierro, Majadahonda, Spain.
  • Glenthøj A; ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Stoma I; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar.
  • Rácil Z; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Piukovics K; King's College Hospital, London, UK.
  • Navrátil M; King's College London, London, UK.
  • Emarah Z; University Hospital Centre Rijeka, Rijeka, Croatia.
  • Sili U; Croatian Cooperative Group for Hematological Diseases (CROHEM), Zagreb, Croatia.
  • Maertens J; Faculty of Medicine and Faculty of Health Studies, University of Rijeka, Rijeka, Croatia.
  • Blennow O; Zealand University Hospital, Roskilde, Roskilde, Denmark.
  • Bergantim R; Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • García-Vidal C; Rigshospitalet, Copenhagen, Denmark.
  • Prezioso L; Gomel State Medical University, Gomel, Belarus.
  • Guidetti A; Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
  • Del Principe MI; Department of Internal Medicine, Albert Szent-Györgyi Health Center, Faculty of Medicine, University of Szeged, Szeged, Hungary.
  • Popova M; University Hospital Ostrava, Ostrava, Czech Republic.
J Hematol Oncol ; 14(1): 168, 2021 10 14.
Article in English | MEDLINE | ID: covidwho-1468074
ABSTRACT

BACKGROUND:

Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality.

METHODS:

The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020.

RESULTS:

The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March-May 2020) and the second wave (October-December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases.

CONCLUSIONS:

This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced mortality despite an increase in the number of reported cases.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 Type of study: Diagnostic study / Etiology study / Prognostic study / Risk factors Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: J Hematol Oncol Journal subject: Hematology / Neoplasms Year: 2021 Document Type: Article Affiliation country: S13045-021-01177-0

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 Type of study: Diagnostic study / Etiology study / Prognostic study / Risk factors Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: J Hematol Oncol Journal subject: Hematology / Neoplasms Year: 2021 Document Type: Article Affiliation country: S13045-021-01177-0